Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "iNGEN"

248 News Found

EU nod to Rezurock for chronic GVHD in adults & teens
News | April 08, 2026

EU nod to Rezurock for chronic GVHD in adults & teens

Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation


ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
News | April 03, 2026

ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses

Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology


Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
News | April 02, 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio


Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
News | April 01, 2026

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions


Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
News | March 28, 2026

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones


Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global
News | March 23, 2026

Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global

India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026


Pfizer warns shareholders against Tutanota’s mini-tender offer
News | March 21, 2026

Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer


Finerenone hits major goal in Phase III FIND-CKD trial
Clinical Trials | March 16, 2026

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk


PK Healthcare granted accreditation under 6th edition by NABH
News | March 05, 2026

PK Healthcare granted accreditation under 6th edition by NABH

The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems